Kiora Pharmaceuticals, Inc.
As of Oct 22, 2026, Kiora Pharmaceuticals is in Stage 3, the topping phase, now in its first week (since Oct 21, 2026). It closed at $2.32, 18.9% below its 52-week high and below its 200-day average, which is rising.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is KPRX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
KPRX among Biotechnology209th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …209 | KPRX | Stage 3 · wk 1 | 49 | −11.5% |
Kiora Pharmaceuticals: quick answers
What stage is Kiora Pharmaceuticals in?
As of Oct 22, 2026, Kiora Pharmaceuticals (KPRX) is in Stage 3, the topping phase. It entered Stage 3 on Oct 21, 2026 and is in its first week there. What the four stages mean
Is Kiora Pharmaceuticals in an uptrend?
Its uptrend has stalled. Kiora Pharmaceuticals is in Stage 3, the topping phase that follows an advance. It trades 4.0% below its 200-day average, which is rising.
How far is Kiora Pharmaceuticals from its 52-week high?
Kiora Pharmaceuticals closed at $2.32 on Oct 22, 2026, 18.9% below its 52-week high of $2.86. Its 52-week low is $1.80.
How has Kiora Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Kiora Pharmaceuticals is down 6.1% over the past year and up 14.9% so far in 2026.
Which sector and industry is Kiora Pharmaceuticals in?
Kiora Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.